Show simple item record

Co-formulation of the rF1V plague vaccine with depot-formulated cytokines enhances immunogenicity and efficacy to elicit protective responses against aerosol challenge in mice

dc.contributor.authorDarrell R. Galloway
dc.contributor.authorJiahui Li
dc.contributor.authorNguyen X. Nguyen
dc.contributor.authorFrank W. Falkenberg
dc.contributor.authorFrank W. Falkenberg
dc.contributor.authorLisa Henning
dc.contributor.authorRobert Krile
dc.contributor.authorYing-Liang Chou
dc.contributor.authorJames N. Herron
dc.contributor.authorJ. Scott Hale
dc.contributor.authorE. Diane Williamson
dc.contributor.otherDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, United States
dc.contributor.otherDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, United States
dc.contributor.otherDepartment of Pathology, Division of Microbiology and Immunology, University of Utah, Salt Lake City, UT, United States
dc.contributor.otherCIRES, GmbH, Bochum, Germany
dc.contributor.otherCyTuVax BV, Maastricht, Netherlands
dc.contributor.otherBattelle Biomedical Research Center, Columbus, OH, United States
dc.contributor.otherBattelle Biomedical Research Center, Columbus, OH, United States
dc.contributor.otherBattelle Biomedical Research Center, Columbus, OH, United States
dc.contributor.otherDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, United States
dc.contributor.otherDepartment of Pathology, Division of Microbiology and Immunology, University of Utah, Salt Lake City, UT, United States
dc.contributor.otherChemical Biological Radiological Division, Defense Science and Technology Laboratory (DSTL), Porton Down, Salisbury, United Kingdom
dc.date.accessioned2025-10-09T05:32:51Z
dc.date.available2025-10-09T05:32:51Z
dc.date.issued01-03-2024
dc.identifier.urihttps://www.frontiersin.org/articles/10.3389/fimmu.2024.1277526/full
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/41152
dc.description.abstractThis study evaluated a depot-formulated cytokine-based adjuvant to improve the efficacy of the recombinant F1V (rF1V) plague vaccine and examined the protective response following aerosol challenge in a murine model. The results of this study showed that co-formulation of the Alhydrogel-adsorbed rF1V plague fusion vaccine with the depot-formulated cytokines recombinant human interleukin 2 (rhuIL-2) and/or recombinant murine granulocyte macrophage colony-stimulating factor (rmGM-CSF) significantly enhances immunogenicity and significant protection at lower antigen doses against a lethal aerosol challenge. These results provide additional support for the co-application of the depot-formulated IL-2 and/or GM-CSF cytokines to enhance vaccine efficacy.
dc.language.isoEN
dc.publisherFrontiers Media S.A.
dc.subject.lccImmunologic diseases. Allergy
dc.titleCo-formulation of the rF1V plague vaccine with depot-formulated cytokines enhances immunogenicity and efficacy to elicit protective responses against aerosol challenge in mice
dc.typeArticle
dc.description.keywordsvaccination
dc.description.keywordsplague vaccine
dc.description.keywordscytokine depot adjuvant
dc.description.keywordsYersinia pestis
dc.description.keywordssubunit vaccine
dc.description.keywordsco-immunization
dc.description.doi10.3389/fimmu.2024.1277526
dc.title.journalFrontiers in Immunology
dc.identifier.e-issn1664-3224
dc.identifier.oaioai:doaj.org/journal:11996e242cf74db8938ba29f3837f5e6


This item appears in the following Collection(s)

Show simple item record